“As healthcare increasingly moves closer to patients, pharmaceutical companies need to combine drug containment and delivery from the outset,” says Christian Mias, CEO of SCHOTT Pharma. “Together with Nemera, we are helping them address this growing demand through a proven and compatible platform solution.”

“Our collaboration with SCHOTT Pharma reflects our commitment to providing integrated drug delivery solutions that help simplify development and accelerate time to market”, says Marc Hämel, CEO of Nemera. “At Nemera, we believe that strong partnerships are essential to helping pharmaceutical companies bring combination products to patients more efficiently.”

Strategic partnership to address evolving patient needs

As therapeutic combination products require seamless integration between the delivery device and the pharmaceutical primary packaging system, Nemera’s and SCHOTT Pharma’s partnership supports optimal product performance as well as patient safety and comfort.

With more than two decades of experience in high-volume manufacturing of pen injectors and autoinjectors, Nemera offers a comprehensive portfolio of proprietary pen injector platforms developed with full intellectual property ownership. These platforms are designed to accommodate a broad range of prescription therapies, address diverse patient needs, and are manufactured in Nemera’s state-of-the-art facilities using advanced automation technologies.

At the same time, SCHOTT Pharma’s cartriQ ready-to-use (RTU) glass cartridge system, manufactured from FIOLAX Type I borosilicate glass with controlled hydrolytic resistance, is specifically designed to meet the demanding requirements of pen injectors, autoinjectors, and pump systems. Its robust mechanical resistance, excellent cosmetic quality, and tight dimensional tolerances support precise processing and reliable device functionality. Quality is ensured through 100% camera-controlled inspection, while geometric tolerances exceed ISO 13926-1 standards and can be further tightened for highly demanding applications.

Precisely controlled inner and outer diameters of the cartridge contribute to improved manufacturing robustness, enhanced visual inspection performance, and greater dose accuracy. In particular, tightly controlled inner diameters help minimize overfill losses in multidose applications, while advanced defect detection capabilities support cartridge integrity, sterility, and overall product quality.

Verified compatibility reduces risk and accelerates development

A comprehensive study was conducted by Nemera’s laboratory in Poland on the mechanical and chemical performance of 3 mL cartriQ RTU cartridges.

The evaluation focused on critical performance parameters, including break-loose and gliding forces (BLGF), as well as inorganic and organic leachable profiles, following accelerated aging conditions. Testing was performed in accordance with recognized industry standards, including ISO 21881 and ICH Q3D guidelines.

To further assess compatibility, additional assessments covered dimensional accuracy, filling volume performance, air-bubble evaluation, and density measurements. SCHOTT Pharma’s glass cartridge system met all predefined acceptance criteria, demonstrating excellent compatibility with Nemera’s pen injector platforms and providing high confidence in the combined solution.

The successful completion of these evaluations confirms the full technical compatibility between the respective products from Nemera and SCHOTT Pharma. Pharmaceutical companies can therefore benefit from a commercially available, verified integrated solution that accelerates development timelines while mitigating technical risks associated with combination products.

Together, Nemera and SCHOTT Pharma are committed to supporting pharmaceutical partners with high-quality, reliable solutions for injectable drug delivery—ultimately helping patients access treatments that are safe, effective, and easy to use.

Further information at www.schott-pharma.com